Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells

Cancer Immunology, Immunotherapy

Volumn 55, Issue 11, 2006, Pages 1384-1395

  Chiang, Cheryl L L ^a   Ledermann, Jonathan A ^b   Rad, Ariel N ^a   Katz, David R ^a   Chain, Benjamin M ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Dendritic cells; HER 2 neu; Hypochlorous acid; MUC 1; Ovarian carcinoma

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; HLA A2 ANTIGEN; HYPOCHLOROUS ACID; MUCIN 1; TUMOR ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CELL ACTIVATION; CELL DEATH; CELL KILLING; CELL LINE; CELL MATURATION; CELL SPECIFICITY; CELL STRAIN SK OV 3; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN CELL; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INTERFERON PRODUCTION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MINIMAL RESIDUAL DISEASE; MONOCYTE; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; OXIDATION; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR CLASSIFICATION;

CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; HUMANS; HYPOCHLOROUS ACID; IMMUNOTHERAPY; INTERFERON TYPE II; OVARIAN NEOPLASMS; OXYGEN; PEPTIDES; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 33746894710     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-006-0127-9     Document Type: Article

References (32)

1. Allison ME, Fearon DT (2000) Enhanced immunogenicity of aldehyde-bearing antigens: a possible link between innate and adaptive immunity. Eur J Immunol 30:2881-2887
2. Barratt-Boyes SM, Vlad A, Finn OJ (1999) Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin Cancer Res 5:1918-1924
3. Basu S, Binder RJ, Suto R, Anderson KM, Srivastava PK (2000) Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol 12:1539-1546
4. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee HG, Kanz L, Brugger W (1999) Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309-4317
5. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102-3108
6. Cerundolo V, Hermans IF, Salio M (2004) Dendritic cells: a journey from laboratory to clinic. Nat Immunol 5:7-10
7. Chen Z, Moyana T, Saxena A, Warrington R, Jia Z, Xiang J (2001) Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells. Int J Cancer 93:539-548
8. Disis ML, Schiffman K (2001) Cancer vaccines targeting the HER2/neu oncogenic protein. Semin Oncol 28:12-20
9. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624-2632
10. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
11. Gritzapis AD, Sotiriadou NN, Papamichail M, Baxevanis CN (2004) Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors. Cancer Immunol Immunother 53:1027-1040
12. Hernando JJ, Park TW, Kubler K, Offergeld R, Schlebusch H, Bauknecht T (2002) Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 51:45-52
13. Holmberg LA, Sandmaier B (2004) Vaccination as a treatment for breast or ovarian cancer. Expert Rev Vaccines 3:269-277
14. Hwu P, Freedman RS (2002) The immunotherapy of patients with ovarian cancer. J Immunother 25:189-201
15. Kotera Y, Shimizu K, Mule JJ (2001) Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res 61:8105-8109
16. Marcinkiewicz J (1997) Neutrophil chloramines: missing links between innate and acquired immunity. Immunol Today 18:577-580
17. Marcinkiewicz J, Chain BM, Olszowska E, Olszowski S, Zgliczynski JM (1991) Enhancement of immunogenic properties of ovalbumin as a result of its chlorination. Int J Biochem 23:1393-1395
18. Marcinkiewicz J, Olszowska E, Olszowski S, Zgliczynski JM (1992) Enhancement of trinitrophenyl-specific humoral response to TNP proteins as the result of carrier chlorination. Immunology 76:385-388
19. Morisaki T, Matsumoto K, Onishi H, Kuroki H, Baba E, Tasaki A, Kubo M, Nakamura M, Inaba S, Yamaguchi K, Tanaka M, Katano M (2003) Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives. Hum Cell 16:175-182
20. Murray JL, Gillogly ME, Przepiorka D, Brewer H, Ibrahim NK, Booser DJ, Hortobagyi GN, Kudelka AP, Grabstein KH, Cheever MA, Ioannides CG (2002) Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8:3407-3418
21. Palmer K, Moore J, Everard M, Harris JD, Rodgers S, Rees RC, Murray AK, Mascari R, Kirkwood J, Riches PG, Fisher C, Thomas JM, Harries M, Johnston SR, Collins MK, Gore ME (1999) Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma. Hum Gene Ther 10:1261-1268
22. Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, Fay J, Banchereau J (2003) Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother 26:432-439
23. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432-436
24. Rad AN, Pollara G, Sohaib SM, Chiang C, Chain BM, Katz DR (2003) The differential influence of allogeneic tumor cell death via DNA damage on dendritic cell maturation and antigen presentation. Cancer Res 63:5143-5150
25. Renard V, Sonderbye L, Ebbehoj K, Rasmussen PB, Gregorius K, Gottschalk T, Mouritsen S, Gautam A, Leach DR (2003) HER-2 DNA and protein vaccines containing potent Th cell epitopes induce distinct protective and therapeutic antitumor responses in HER-2 transgenic mice. J Immunol 171:1588-1595
26. Santin AD, Bellone S, Palmieri M, Bossini B, Cane S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S (2004) Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. Int J Gynecol Cancer 14:64-75
27. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells [see comments]. J Exp Med 191:423-434
28. Schuler G, Schuler-Thurner B, Steinman RM (2003) The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 15:138-147
29. Shaif-Muthana M, McIntyre C, Sisley K, Rennie I, Murray A (2000) Dead or alive: immunogenicity of human melanoma cells when presented by dendritic cells. Cancer Res 60:6441-6447
30. Slingluff CL Jr, Petroni GR, Yamshchikov GV, Barnd DL, Eastham S, Galavotti H, Patterson JW, Deacon DH, Hibbitts S, Teates D, Neese PY, Grosh WW, Chianese-Bullock KA, Woodson EM, Wiernasz CJ, Merrill P, Gibson J, Ross M, Engelhard VH (2003) Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 21:4016-4026
31. Wolpoe ME, Lutz ER, Ercolini AM, Murata S, Ivie SE, Garrett ES, Emens LA, Jaffee EM, Reilly RT (2003) HER-2/neuspecific monoclonal antibodies collaborate with HER-2/neutargeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice. J Immunol 171:2161-2169
32. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348:203-213